Scarica l'app Stockscreener
0.82
2.50%
0.02
Precedente Chiudi:
$0.80
Aprire:
$0.75
Volume 24 ore:
4,136
Relative Volume:
10.85
Capitalizzazione di mercato:
$N/A
Reddito:
$257.55M
Utile/perdita netta:
$11.95M
Rapporto P/E:
0.9011
EPS:
0.91
Flusso di cassa netto:
$-9.39M
1 W Prestazione:
+16.07%
1M Prestazione:
-76.15%
6M Prestazione:
-81.21%
1 anno Prestazione:
-93.26%
Intervallo 1D:
$0.75
$0.82
Intervallo di 1 settimana:
$0.66
$0.82
Portata 52W:
$0.66
$0.82
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
Confronta EGRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EGRX
Eagle Pharmaceuticals Inc
|
0.82 | 0 | 257.55M | 11.95M | -9.39M | 0.91 |
|
ZTS
Zoetis Inc
|
171.03 | 77.44B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.55 | 43.22B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.53 | 42.94B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.84 | 18.94B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
127.11 | 13.51B | 612.78M | -86.37M | -62.91M | -0.87 |
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2018-11-01 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2018-10-31 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2018-03-21 | Reiterato | Mizuho | Underperform |
| 2017-11-09 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-06 | Reiterato | Mizuho | Underperform |
| 2017-07-27 | Reiterato | Mizuho | Underperform |
| 2017-07-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-05-09 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-01-09 | Downgrade | Mizuho | Neutral → Underperform |
| 2016-11-16 | Downgrade | Mizuho | Buy → Neutral |
| 2016-11-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2016-11-03 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-26 | Reiterato | Mizuho | Buy |
| 2016-08-16 | Reiterato | Mizuho | Neutral |
| 2016-06-20 | Downgrade | Mizuho | Buy → Neutral |
| 2016-05-10 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-03-18 | Reiterato | Mizuho | Buy |
| 2016-02-26 | Reiterato | Mizuho | Buy |
| 2015-12-09 | Iniziato | Mizuho | Buy |
| 2015-07-29 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Eagle Pharmaceuticals Inc Borsa (EGRX) Ultime notizie
EGRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eagle Pharmaceuticals, Inc. Enters Third Amended and Restated Credit Agreement - Marketscreener.com
StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com - Defense World
Jane Street Group LLC Makes New Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.09% - MSN
Antiemetics Drugs Market Size & Share Report, 2024 – 2032 - Global Market Insights
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - Defense World
Last Week's Biggest Stock Movers: Eagle, Noodles & Co. - AOL
Eagle Pharmaceuticals Enters Into Settlement Agreement With Dr. Reddy's Laboratories on Leukemia Drug - Marketscreener.com
Eagle Pharmaceuticals : to Present at Jefferies Virtual Healthcare Conference 2021 - Marketscreener.com
Eagle Pharmaceuticals Amends Rights Agreement with Equiniti Trust Company - Defense World
Eagle Pharmaceuticals amends rights agreement - Investing.com
Eagle Pharmaceuticals amends rights agreement By Investing.com - Investing.com Nigeria
Eagle Pharmaceuticals Dismisses Ernst & Young LLP as Independent Registered Public Accounting Firm - Defense World
Eagle Pharmaceuticals switches to BDO after Ernst & Young dismissal - Investing.com
Eagle Pharmaceuticals switches to BDO after Ernst & Young dismissal By Investing.com - Investing.com UK
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceutica - GuruFocus.com
Eagle Pharma Founder Sues Company to Recoup Cost of SEC Investigation - Law.com
Ex-Pharma CEO Demands Legal Fees For SEC Probe - Law360
Eagle Pharmaceuticals names Christopher Krawtschuk as CFO - MSN
Eagle Pharmaceuticals to Delist from Nasdaq By Investing.com - Investing.com Australia
Eagle Pharmaceuticals, Inc. Announces Executive Changes - Marketscreener.com
Eagle Pharmaceuticals to Delist from Nasdaq - Investing.com India
Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration - The Manila Times
Eagle Pharmaceuticals to Complete Nasdaq Delisting After Trading Suspension | EGRX Stock News - StockTitan
Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Citigroup Inc's Strategic Reduction in Eagle Pharmaceuticals Inc Shares - GuruFocus.com
Creative Planning Makes New $59,000 Investment in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial OfficerWOODCLIFF LAKE, N.J. — November 12, 2024 — Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) recently announced the appointment of Christopher Krawtschuk as the Chief - Defense World
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer - The Manila Times
Eagle Pharmaceuticals, Inc. Announces Chief Financial Officer Changes - Marketscreener.com
Some Major Key Players In The Heparin-Induced Thrombocytopenia (HIT) Treatment Market: - InsightAce Analytic
Nantahala Capital Management Reduces Stake in Eagle Pharmaceuticals - GuruFocus.com
Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’S Disease in Collaboration with University of Pennsylvania - Marketscreener.com
Eagle Pharmaceuticals Adopts Stockholder Rights Plan to Protect Shareholders’ Interests - Defense World
Union Square Park Capital Management, LLC Increases Stake in Eagle Pharmaceuticals Inc - GuruFocus.com
Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan - The Manila Times
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle - GlobeNewswire
Pemetrexed Market Is Booming Worldwide 2024-2031 | Stada - openPR
Snowflake, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - ForexTV.com
Snowflake, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire Inc.
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com - Defense World
Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight - GlobeNewswire
Eagle Pharmaceuticals Inc Azioni (EGRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
3.59%
Capitalizzazione:
|
Volume (24 ore):